5-Amino-1MQ
Also known as: 5-Amino-1-Methylquinolinium
Molecular Identifiers
Overview
Selective inhibitor of the enzyme NNMT (nicotinamide N-methyltransferase). Small molecule (not a peptide) that increases cellular NAD+ levels, promoting lipid metabolism and adiposity reduction.
The main interest around 5-Amino-1MQ is its potential as a metabolic agent: by inhibiting the NNMT enzyme, it raises intracellular NAD+ and SAM levels, which translates into increased fatty acid oxidation, reduced adipocyte differentiation, and improved insulin sensitivity in preclinical models. For these reasons it is studied in obesity, hepatic steatosis, and metabolic syndrome.
Although often grouped with peptides, this is a small molecule administered orally in capsules. It has no regulatory approval; it reaches users through compounding pharmacies and research-use suppliers, typically in 4–12 week cycles. Human clinical data is still limited, and current use is grounded mostly in preclinical studies.
Small molecule (not a peptide). Does not have an amino acid sequence.
Half-life
~12 hours (oral)
Administration Route
Oral (capsules)
Category
Metabolic & Fat Loss
Mechanism of Action
- Selective inhibition of NNMT
- Increase in cellular NAD+ levels
- Promotion of fatty acid oxidation
- Reduction of adipocyte differentiation
- Improvement of insulin sensitivity
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 50 mg per capsule |
| Frequency | 1-2 times daily |
| Timing | Morning and/or evening |
| Duration | 4-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild headache
- Nausea
- Gastrointestinal discomfort
Product Properties
| Purity | >98% |
| Appearance | White capsules |
| Solubility | Soluble in DMSO and water |
| Source | Chemical synthesis |
| Storage | Room temperature (15-25°C) in a dry place for up to 2 years. Protect from moisture and direct light. |
Presentations & Preparation
Vials of 5-Amino-1MQ found in the research market:
Reconstitution
- Diluent: N/A (oral capsules)
- Volume: N/A
- Product supplied in ready-made capsules
- No reconstitution required
Storage
- Lyophilized: Room temperature (up to 2 years)
- Reconstituted: N/A (capsules)
- Store in a dry place
- Protect from light and moisture
Scientific Studies
Published studies on 5-Amino-1MQ.
Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice
Neelakantan H, Vance V, Wetzel MD, Wang HL, McHardy SF, Finnerty CC, Hommel JD, Watowich SJ
Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
Kraus D, Yang Q, Kong D, Banks AS, Zhang L, Rodgers JT, Pirinen E, Pulinilkunnil TC, Gong F, Wang YC, Cen Y, Sauve AA, Asara JM, Peroni OD, Monia BP, Bhanot S, Alhonen L, Puigserver P, Kahn BB
Related Peptides
Adipotide
0.03 mg/kg body weight (Phase 1 trial starting dose) · Once daily
AICAR
0.1 mg/kg/min by intravenous infusion (CABG trial dose) · Single continuous infusion
AOD 9604
300-600 mcg per injection · Once daily
Cagrilintide
1.2-4.5 mg per week (subcutaneous) · Once weekly
Dulaglutide
0.75-4.5 mg per week (subcutaneous) · Once weekly
Exenatide
5-10 mcg per injection (subcutaneous) · Twice daily (Byetta) or once weekly (Bydureon)